Alexion seeks approval from FDA for PNH drug ALXN1210

This article was originally published here

Alexion Pharmaceuticals said that it has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA), seeking approval for its C5 complement inhibitor ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply